Q-omics provides the consensus-scored CSGALNACT2P1 profile across patient tissues and cancer cell-line models. CSGALNACT2P1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CSGALNACT2P1 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, CSGALNACT2P1 RNA expression shows 15,392 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, HNSC, and UVM as cancer lineages where CSGALNACT2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSGALNACT2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSGALNACT2P1 survival associations across molecular data types. CSGALNACT2P1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSGALNACT2P1 RNA expression–survival associations across cancer types. High CSGALNACT2P1 expression shows unfavorable associations in KICH, KIRP and MESO, but favorable associations in ESCA, ACC and LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CSGALNACT2P1 RNA expression.
This table summarizes CSGALNACT2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSGALNACT2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSGALNACT2P1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, LUSC, UCEC and LIHC. The HNSC box plot shows higher CSGALNACT2P1 RNA expression in tumor versus normal tissue (log2 FC = +1.053, t-test p < 0.001).
This table shows molecular features associated with CSGALNACT2P1 in patient tissues and cancer cell lines. In patient samples, CSGALNACT2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
